IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has been given a consensus rating of “Moderate Buy” by the sixteen brokerages that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation, thirteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $53.67.

IDYA has been the subject of several recent research reports. Stephens assumed coverage on shares of IDEAYA Biosciences in a research report on Monday, November 18th. They set an “overweight” rating and a $51.00 target price for the company. Leerink Partners lowered IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and cut their target price for the company from $41.00 to $27.00 in a research note on Tuesday, November 5th. Royal Bank of Canada restated an “outperform” rating and set a $61.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday, September 24th. Oppenheimer reiterated an “outperform” rating and issued a $53.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday, October 29th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $52.00 target price on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th.

Institutional Investors Weigh In On IDEAYA Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of IDYA. Allworth Financial LP grew its stake in shares of IDEAYA Biosciences by 800.0% during the 3rd quarter. Allworth Financial LP now owns 900 shares of the company’s stock worth $29,000 after acquiring an additional 800 shares in the last quarter. Covestor Ltd boosted its holdings in IDEAYA Biosciences by 23,050.0% during the third quarter. Covestor Ltd now owns 926 shares of the company’s stock worth $29,000 after purchasing an additional 922 shares during the last quarter. Quest Partners LLC bought a new position in IDEAYA Biosciences in the second quarter valued at $41,000. US Bancorp DE increased its stake in IDEAYA Biosciences by 67.2% in the 3rd quarter. US Bancorp DE now owns 1,714 shares of the company’s stock valued at $54,000 after buying an additional 689 shares during the last quarter. Finally, Daiwa Securities Group Inc. increased its stake in IDEAYA Biosciences by 637.9% in the 2nd quarter. Daiwa Securities Group Inc. now owns 1,948 shares of the company’s stock valued at $68,000 after buying an additional 1,684 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences Stock Down 2.2 %

Shares of IDYA opened at $24.85 on Friday. The stock’s fifty day simple moving average is $26.98 and its 200-day simple moving average is $32.77. The firm has a market capitalization of $2.15 billion, a PE ratio of -10.67 and a beta of 0.82. IDEAYA Biosciences has a 12-month low of $24.20 and a 12-month high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last released its earnings results on Monday, November 4th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.03. During the same quarter last year, the company earned ($0.46) EPS. Analysts anticipate that IDEAYA Biosciences will post -2.45 EPS for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.